Amicus Therapeutics and GlaxoSmithKline have expanded their collaboration to develop and commercialize the investigational pharmacological chaperone migalastat HCl for Fabry disease.   The expanded alliance includes co-development of all current and future formulations of migalastat HCl, including a co-formulation of migalastat HCl with GSK/JCR Pharmaceutical Co.’s enzyme replacement therapy (ERT) for Fabry disease. Amicus will have commercial rights to all Fabry products in the U.S. and G...